Dr. Peter H Kay.

Details

My background

I am a retired Australia trained Molecular Pathologist, Immunopathologist and Cancer specialist. I have taught these subjects at the University of Western Australia for many years. I have carried out research in these areas and published over 80 papers in world class scientific outlets. I have lectured to hundreds of under-graduate students and supervised many post-graduate students helping them to progress along their chosen career pathway. I teach from the basics of chemistry and biology to more complex matters to do with th medical sciences.
To help all health practitioners, students of the medical sciences, I have prepared full courses on Integrative Oncology and Integrative Immunopathology as well as a course entitled "How to become a world-class professional researcher." Course synopses may be obtained from Scholar Hub.

Experience

Myacademic C.V. is now included.
ACADEMIC CURRICULUM VITAE.
Dr. Peter H. Kay (PhD).
Address: 36, Woodplumpton Road, Woodplumpton, Preston, PR4 0NE, U.K.
Tel: (H). +44 (0) 1772 691443
Email: peterhkay@gmail.com
Nationality: British.
Date of Birth: 4th April, 1945.
Experiences.
1993-2001, Co-ordinator of Human Oncobiology third year undergraduate course, Faculty of Science, the University of Western Australia.
1989-2001, Department of Pathology, Faculty of Dentistry and Medicine, the University of Western Australia. Senior Lecturer and Head of the Molecular Pathology Laboratory.
1989, Founder of the Molecular Pathology Laboratory, Department of Pathology, Faculty of Dentistry and Medicine, the University of Western Australia.
1979-1988, Division of Immunopathology, Department of Pathology, Faculty of Dentistry and Medicine, the University of Western Australia. Senior Scientist, immunopathology, immunology, immunogenetics and molecular genetics. Lecturer/scientist.
1974-1978, Department of Clinical Immunology, Royal Perth Hospital, Perth, Western Australia.
Lecturer/Scientist.
1965-1973, Blood Transfusion Centre, Lancaster, UK, Scientist, Blood Group Serology, Immunochemistry and Haematology.
Qualifications:-
PhD (Immunogenetics, the University of Western Australia).
HNC (UK) (Haematology and Serology).
FIMLS (UK).

Member of grant application assessment panel for:-
National Health and Medical Research Council of Australia, 1988-2001.
Health Research Council of New Zealand, 1992-2001.
Anti-Cancer Council of Victoria, 1990-2001.
Anti-Cancer Foundation of South Australia, 1993-2001.

Major competitive grants awarded:-

Kay PH, et al. NH&MRC, 1996-1998, $160,000.
Hähnel R, Kay PH, Byrne M. Cancer Foundation of W.A., 1997, $43,000.
Kay PH, Spagnolo DV, Papadimitriou JM. MEDWA, 1995-1996, $80,000.
Kay PH, Papadimitriou JM. Raine Foundation of W.A., 1993-1995, $240,000.
Kay PH, Grounds MD, Papadimitriou JM. NH&MRC, 1990-1992, $95,000.

Post-graduate students as PRINCIPAL supervisor (1990-2001):-

PhD:- Passed 6.
MSc:- Passed 1.
BSc (Hons):- Passed 10.
Graduate Diploma:- Passed 1.

Post-graduate students as co-supervisor.
Many.

Post Doctoral supervision/training:-
Dr. A. Bagwe. (Supported by the Biotechnology Department of
Government of India for Post-Doctoral Cancer Research Training, (1997-1998).

Academic Publications:-
Invited reviews:

Kay PH, Spagnolo DV, Taylor JME, Ziman M. DNA methylation and developmental
genes in lymphomagenesis - more questions than answers? Leukemia Lymphoma 24:211-
220. (1997).

Kay PH, Jacobsen PF, Taylor J, Spagnolo DV. The significance of DNA methylation in
cancer. Adv Anat Path 2:353-361. (1995).

Kay PH, Papadimitriou JM. What's new in the role of complement in disease? Path Res
Pract 186:410-414. (1990).



Invited chapters in book:-
Taylor JME, Kay PH, Spagnolo DV. The diagnostic and prognostic significance of the
methylation status of Myf-3 in lymphoproliferative disorders. In: Molecular Diagnosis of
Cancer. Eds. J.Bartlett, J. Roulston. Humana Press, Totowa. (2002).

Kay PH, Dawkins RL. Complement genetics and disease. In: Complement in Health and
Disease. Ed. K. Whaley. MTP Press, Lancaster. (1986).

List of refereed publications:-

Pelham J. Irwin PJ, Kay PH. Genomic hypomethylation in neoplastic cells from dogs
with lymphoproliferative disorders. Res Vet Sci 74: 101-4 (2003).

Franchina M, Kay PH. DNMT1 Gene copy number does not influence susceptibility to
malignant lymphoproliferative disease. Anti-Cancer Res 22:3405-7 (2002).

Taylor JM, Kay PH, Spagnolo DV. The diagnostic significance of Myf-3
hypermethylation in malignant lymphoproliferative disorders. Leukemia. 15:583-589 (2001).

Franchina M, Hooper J, Kay PH. Five novel alternatively spliced transcripts of DNA
(cytosine-5) methyltransferase2 in human peripheral blood leukocytes. Int J of Biochem
Cell Biol 33: 1104-1115 (2001).

Franchina M, Kay PH. Novel nucleotide substitutions within the coding region of
DNMT2 are in strong linkage disequilibrium in Caucasians and Japanese. Hum Hered
52: 210-216 (2001).

Franchina M, Kay PH. Evidence that cytosine residues within 5’-CCTGG-3’
pentanucleotides can be methylated in human DNA independently of the methylating
system which modifies 5’-CG-3’ dinucleotides. DNA Cell Biol 19:521-526 (2000).

Butler TL, Kay PH, Jacobsen, PF. Hypomethylation of cytosine 5-methyltransferase in
human neoplasms. Anti-cancer Res 20:1435-1438 (2000).

Franchina M, Kay PH. Allele-specific variation in the gene copy number of human
cytosine 5-methyltransferase. Hum Hered 50:112-117 (2000).

Rodger J, Ziman MR, Papadimitriou JM, Kay PH. Pax7 is expressed in the capsules
surrounding adult mouse neuromuscular spindles. Biochem Cell Biol 77:153-156 (1999).

Kay PH, Ziman MR. Alternate Pax7 paired box transcripts which include a trinucleotide
or a hexanucleotide are generated by use of alternate 3’ intronic splice sites which are not
utilised in the ancestral homologue. Gene 230:55-60 (1999).

Shannon B, Kay PH, House A, Iacopetta B. Hypermethylation of the Myf-3 gene in
colorectal cancers: associations with pathological features and with microsatellite
instability. Int J Cancer 84:109-113 (1999).

Ziman MR, Kay PH. A conserved TN8TCCT motif in the octopeptide encoding region of
Pax genes which has the potential to direct cytosine methylation. Gene 223:303-308
(1998).

Ziman MR, Kay PH. Differential expression of four alternate Pax7 paired box transcripts
is influenced by organ and strain specific factors in adult mice. Gene 217:77-81 (1998).

Kay PH, Hahnel R, Gunn H, Harmon, Song J. Hypermethylation of Hpall recognition
sequences within the 5’ coding region of the estrogen receptor gene is not associated with
estrogen receptor negativity in primary breast tumours. Anti-cancer Res. 18:1709-1712
(1998).

Bagwe AN, Ahmed MO, Franchina M, Spagnolo DV, Papadimitriou JM, Kay PH. A
novel Msp1 PCR-RFLP in the human cytosine 5 methyltransferase gene: lack of relevance
for malignant lymphoproliferative disease and breast cancer. Hum Hered 48:226-229
(1998).

Kay PH, Harmon D, Fletcher S, Robertson T, Ziman M, Papadimitriou JM. Pax7
includes two polymorphic homeoboxes which contain rearrangements associated with
differences in the ability to regenerate damaged skeletal muscle in adult mice. Int J
Biochem Cell Biol 30:261-269 (1998).

Bagwe AN, Kay PH, Spagnolo DV. Evidence that DNA methylation imbalance is not
involved in the development of malignant mesothelioma. Anticancer Research 17:3341-
3344 (1997).

Taylor JM, Spagnolo DV, Kay PH. B-cell target DNA quantity is a critical factor in the
interpretation of B-cell clonality by PCR. Pathology 29:309-312 (1997).

Ziman MR, Fletcher S, Kay PH. Alternate Pax7 transcripts are expressed specifically in
skeletal muscle, brain and other organs of adult mice. Int J Biochem Cell Biol 29:1029-
1036 (1997).

Kay PH, Harmon D, Fletcher S, Ziman M, Jacobsen PF, Papadimitriou JM. Variation in
the methylation profile and structure of Pax3 and Pax7 among different mouse strains and
during expression. Gene 184:45-53 (1997).

Kay PH, Spagnolo DV, Taylor J, Ziman M. DNA methylation and developmental genes
in lymphomagenesis - more questions than answers? Leukemia Lymphoma 24:211-220
(1997).

Marlow SA, Kay PH, McGeachie JK, Papadimitriou JM. Investigation of the influence of
the Mm musculus Myo D1 allele on the efficiency of skeletal muscle regeneration . J Anat
190:223-227 (1997).

Iacopetta BJ, Harmon D, Spagnolo DV, House AK, Kay PH. Hypermethylation of the
Myf-3 gene in human colorectal cancer. Anticancer Res 17:429-432 (1997).

Harmon D, Kay PH. Polymorphism of Pax7 in the wild mouse gene pool. Mouse
Genome 94:868-870 (1996).

Hähnel R, Harvey J, Kay PH. Hypermethylation of the myogenic gene Myf-3 in human
breast carcinomas. Anticancer Res 16:2111-2116 (1996).

Marlow SA, Kay PH, Papadimitriou JM. Polymorphism of the mouse E2A gene due to
an intronic deletion of 536 bp. Gene 168:143-149 (1996).

Kay PH, Jacobsen PF, Taylor J, Spagnolo DV. The significance of DNA methylation in
cancer. Adv Anat Path 2:353-361 (1995).

Lynch DM, Kay PH. Studies on the polymorphism of the fifth component of complement
in laboratory mice. Exp Clin Immunogenet 12:253-260 (1995)

Kay PH, Mitchell CA, Akkari A, Papadimitriou JM. Association of an unusual form of a
Pax7-like gene with increased efficiency of skeletal muscle regeneration. Gene 163:171-
177 (1995).

Kay PH, Taylor J, Kees UR, Baker DL, Spagnolo DV. Myf-3 hypermethylation in
malignant lymphoproliferative disorders. Int J Cancer 62:797-799 (1995).

Marlow SA, Kay PH, Papadimitriou JM. Myo-D1 alleles distinguish between Mm
domesticus and Mm musculus subspecies. Mouse Genome 93:436-438 (1995).

Marlow SA, Kay PH, Papadimitriou JM. Polymorphism of the murine inhibitor of
differentiation-controlling gene Id. Gene 153:281-282 (1995).

Ashman RB, Kay PH, Lynch DM, Ott K. Association of a complement allotype (C3F)
with acute inflammatory responses to Candida albicans infection . Med J Aust 160:732-
733 (1994).

Spagnolo DV, Taylor J, Carrello S, Saueracker E, Kay PH. Southern blot analysis of
lymphoproliferative disorders : use and limitations in routine surgical pathology.
Pathology 26:268-275 (1994).

Kay PH, Pereira E, Marlow SA, Turbett G, Mitchell CA, Jacobsen PF, Holliday R,
Papadimitriou JM. Evidence for adenine methylation within the mouse myogenic gene
Myo-D1. Gene 151:89-95 (1994).

Marlow SA, Kay PH, Papadimitriou JM. Polymorphism of the mouse transcription
factor-encoding gene E2A. Gene 141:303-304 (1994)

Kay PH, Marlow SA, Mitchell CA, Papadimitriou JM. Studies on the evolution and
function of different forms of the mouse myogenic gene Myo-D1 and upstream flanking
region. Gene 124:215-222 (1993).

Lynch DM, Ashman, RB, Kay PH, Papadimitriou JM. Genetic structural and functional
studies of a complement C3-like protein in the marsupial Setonix brachyurus. Exp Clin
Immunogenet 10:195-201 (1993).

Lynch DM, Kay PH, Papadimitriou, JM, Grounds MD. Studies on the structure of
complement C3 and the stability of C3 derived phagocytic ligands C3b/iC3b in SJL/J and
BALB/c mice. Eur J Immunogenet 20:1-9 (1993).

Pavlovic M, Kay PH, Moriuchi J, Jacobsen PF, Papadimitriou JM. TaqI polymorphism of
the epidermal growth factor receptor gene in Caucasoids and Japanese. Human Heredity
43:39-44 (1993).

Kay PH, Moriuchi J, Ma PJ and Saueracker E. An unusual allelic form of the
immunoglobulin lambda constant region genes in the Japanese. Immunogenetics 35:341-
343 (1992).

Saueracker EA, Kay PH, Spagnolo DV. Distinguishing between monoclonal
rearrangements and allelic forms of the immunoglobulin lambda light chain constant
region genes. Diagn Mol Path 1:109-117 (1992).

Ashman RB, Kay PH, Lynch D, Papadimitriou JM. Murine candidiasis. Sex differences
in the severity of tissue lesions are not associated with levels of serum C3 and C5.
Immunol Cell Biol 69:7-10 (1991).

Kay PH, Jacobsen PF, Zheng M-H, Papadimitriou JM. Genetic polymorphism of the
murine myogenic gene Myo-D1. Gene 99:273-277 (1991).

Kay PH, Marlow S, George A. Heterogeneity of the wild mouse (house mouse) Myo-D1
gene pool in Western Australia. Proc Australian Physiol Pharmacol Soc 22:181-186
(1991).

Uko GP, Dawkins RL, Mohammed I, Kay PH, Christiansen FT, Nasidi A, Bajani M. Bf S
gene frequency in Nigerians with HIV infection. Disease Markers 9:333-338 (1991).

Dawkins RL, Martin E, Saueracker G, Kay PH, Leaver A, Christiansen FT. Supratypes
and ancestral haplotypes in IDDM: potential importance of central non-HLA MHC genes.
J Autoimmunity 1:63-68 (1990).

Kay PH, Papadimitriou JM. What's new in the role of complement in disease? Path Res
& Pract 186:410-414 (1990).

Dawkins RL, Leaver A, Cameron PU, Martin E, Kay PH, Christiansen FT. Some disease associated
ancestral haplotypes carry a polymorphism of TNF. Hum Immunol 26:91-97
(1989).

Tokunaga K, Kay PH, Christiansen FT, Saueracker G, Dawkins RL. Comparative
mapping of the human major histocompatibility complex in different racial groups by
pulsed field gel electrophoresis. Hum Immunol 26:99-106 (1989).

Cameron PU, Cobain TJ, Zhang WJ, Kay PH, Dawkins RL. Influence of C4 null genes
on infection with human immunodeficiency virus. Br Med J Clin Res 296; 1627-1628
(1988).

Kay PH, Dawkins RL, Williamson J, Tokunaga K, Christiansen FT, Charoenwong P.
Coexistence of an MHC chromosomal segment marked by HLA B17, BfS, C4A6, B1,
DR7, and DQw9 in different ethnic groups. Hum Immunol 23:27-35 (1988).

Kay PH, Martin E, Dawkins RL, Charoenwong P. Class III gene rearrangements in
Thai/Chinese supratypes containing null or defective C4 alleles. Immunogenetics 27:46-
50 (1988).

Tokunaga K, Saueracker G, Kay PH, Christiansen FT, Anand R, Dawkins RL. Extensive
deletions and insertions in different MHC supratypes detected by pulsed field gel
electrophoresis. J Exp Med 168:933-940 (1988).

Warlow RS, Uko G, Feeney DJ, Kay PH. HLA, C4, Bf, Gm and autoantibodies in
rheumatoid arthritis. Exp Clin Immunogenet 5:133-142 (1988).

Zhang WJ, Kay PH, Cobain TJ, Dawkins RL. C4 allotyping on plasma or serum:
application to routine laboratories. Hum Immunol 21:165-171 (1988).

Dawkins RL, Kay PH, Garlepp MJ, Christiansen FT. Immunogenetics of spontaneous,
drug-induced, and experimental myasthenia gravis. Ann NY Acad Sci 505:398-406
(1987).

Dawkins RL, Martin E, Kay PH, Garlepp MJ, Wilton AN, Stuckey MS. Heterogeneity of
steroid 21-hydroxylase genes in classical congenital adrenal hyperplasia. J. Immunogenet
14:89-98 (1987).

Kay PH, Dawkins RL, Bowling AT, Bernoco D. Heterogeneity and linkage of equine C4
and steroid 21-hydroxylase genes. J. Immunogenet 14:247-253 (1987).

Kay PH, Dawkins RL, Bowling AT, Bernoco D. Polymorphism of the acetylcholine
receptor in the horse. Veterinary Record 120:363-365 (1987).

Kay PH, Grimsley G, Dawkins RL, Charoenwong P. MHC supratypes as markers of null
and defective C4 alleles in a Thai/Chinese population: relevance to disease susceptibility.
Disease Markers 5:43-47 (1987).

Kay PH, Dawkins RL, Bowling AT, Bernoco D. Electrophoretic polymorphism and
molecular structure of equine C3. Animal Genetics 17:209-215 (1986).

Musk AW, Zilko PJ, Manners P, Kay PH, Kamboh MI. Genetic studies in familial
fibrosing alveolitis. Possible linkage with immunoglobulin allotypes (Gm). Chest 89:206-
210 (1986).

Warlow RS, Uko G, McCluskey J, Kay PH, Christiansen FT, Dawkins RL. Extractable
nuclear antigen (ENA) autoantibodies in SLE: an immunogenetic relationship with HLA,
C4 and Bf alleles. Clin Exp Immunol 63:419-427 (1986).

Day MJ, Kay PH, Clark WT, Shaw SE, Penhale WJ, Dawkins RL. Complement C4
allotype association with and serum C4 concentration in an autoimmune disease in the
dog. Clin Immunol Immunopathol 35:85-91 (1985).

Kay PH, Dawkins RL, Christiansen FT. Sex influences transmission of the supratype,
associated with the C2 deficiency allele: a possible mechanism for the maintenance of
heterozygosity and disease susceptibility. Hum Immunol 12:185-189 (1985).

Kay PH, Dawkins RL, Penhale JW. The molecular structure of different polymorphic
forms of canine C3 and C4. Immunogenetics 21:313-319 (1985).

Kay PH, Natsuume-Sakai S, Hayakawa J, Dawkins RL. Different allotypes of C3,
degrade at different rates. Immunogenetics 22:563-569 (1985).

Kay PH, Wilton AN, Dawkins RL. Preferential paternal transmission of the diabetogenic
supratype marked by HLA B18 BfF1 DR3. Journal of Immunogenetics 12:327-329
(1985).

Kelly H, McCann VJ, Kay PH, Dawkins RL, TI Susceptibility to IDDM is marked by
MHC supratypes rather than individual alleles. Immunogenetics 22:643-651 (1985).

Uko G, Dawkins RL, Kay PH, Christiansen FT, Hollingsworth PN, CR1 deficiency in
SLE: acquired or genetic?. Clin Exp.Immunol 62:329-336 (1985).

Warlow RS, Garlepp M, Feeney D, Kay PH, Swanson N, Dawkins RL. Antiacetylcholine
receptor and antinuclear antibodies in myasthenia gravis. Correlation with HLA, sex and
Gm. Exp Clin Immunogenet 2:158-163 (1985).

Warlow RS, Kay PH, McCluskey J, Uko G, Dawkins RL. Secondary Sjogren's syndrome
and chromosome six markers. Tissue Antigens 25:247-254 (1985).

Garlepp MJ, Kay PH, Farrow BR, Dawkins RL. Autoimmunity in spontaneous
myasthenia gravis in dogs. Clin Immunol Immunopathol 31:301-306 (1984).

Kay PH, Dawkins RL. Genetic polymorphism of complement C4 in the dog. Tissue
Antigens 23:151-155 (1984).

McCann VJ, McCluskey J, Kelly H, Kay PH, Zilko PJ, Christiansen FT, Dawkins RL.
Thyrogastric autoimmunity and MHC associated alleles at the C4 locus in patients with
type 1 (insulin-dependent) diabetes. Diabetologia 27:124-125 (1984).

Beilby JP, Dick M, Kay PH, Watson FE. The microheterogeneities of thyroxine-binding
globulin and alpha 1 protease inhibitor (alpha 1-antitrypsin) are interrelated. Clinica
Chimica Acta 133:51-63, (1983).

Christiansen FT, Dawkins RL, Uko G, McCluskey J, Kay PH, Zilko PJ. Complement
allotyping in SLE: association with C4A null. Aust NZ J Med 13:483-488 (1983).
Dawkins RL, Christiansen FT, Kay PH, Garlepp M, McCluskey J, Hollingsworth PN,
Zilko PJ. Disease associations with complotypes, supratypes and haplotypes. Immunol
Rev 70:1-22 (1983).

Dawkins RL, Kay PH, Christiansen FT. Immunogenetics of rheumatoid arthritis. Ann
Acad Med, Singapore 12:155-163 (1983).

Dawkins RL, Uko G, Christiansen FT, Kay PH. Low C4 concentrations in insulin
dependent diabetes mellitus. [letter]. Br Med J Clin Res 287:839 (1983).

Kay PH, McCluskey J, Christiansen FT, Feeney D, McCann VJ, Zilko PJ, Dawkins RL,
O'Neill GJ. Complement allotyping reveals new genetic markers in rheumatoid arthritis
and diabetes mellitus. Tissue Antigens 21:159-160 (1983).

McCann VJ, McCluskey J, Kay PH, Zilko PJ, Christiansen FT, Dawkins RL. HLA and
complement genetic markers in diabetic retinopathy [letter]. Diabetologia 24:221 (1983).

McCluskey J, , McCann VJ, Kay PH, Zilko PJ, Christiansen FT, O'Neill GJ, Dawkins RL.
HLA and complement allotypes in Type 1 (insulin-dependent) diabetes. Diabetologia
24:162-165 (1983).

McCluskey J, Kay PH, Stuckey M, Christiansen FT, Dawkins RL, Wilson G. MHC
"supratype" predicting heterozygous 21-hydroxylase deficiency [letter]. Lancet 1:764-765
(1983).

Uko G, Christiansen FT, Dawkins RL, Kay PH. Low serum C4 concentrations in insulin
dependent diabetes mellitus. [letter]. Br Med J Clin Res 286:1748-1749, (1983).

Garlepp MJ, Kay PH, Dawkins RL. The diagnostic significance of autoantibodies to the
acetylcholine receptor. J Neuroimmunol 3:337-350 (1982).

O'Neill GJ, Nerl CW, Kay PH, Christiansen FT, McCluskey J, Dawkins RL.
Complement C4 is a marker for adult rheumatoid arthritis [letter]. Lancet 2:214 (1982).

Garlepp MJ, Kay PH, Dawkins RL, Bucknall RC, Kemp A. Cross-reactivity of anti-acetylcholine
receptor autoantibodies.

Qualifications

PhD

Reviews

No reviews yet.